Advancing Care in MASLD Programme | Time (SGT) |
---|---|
Chairs: Dr. Mark Muthiah & Prof. Hirokazu Takahashi | |
Welcome Address – Prof. Arun Sanyal, USAView Bio, Dr. Mark Muthiah, SingaporeView Bio |
|
Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint – Prof. Vincent Wong, Hong Kong View Bio |
|
Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint – Prof. Sven Francque, Belgium View Bio |
|
Similarities and differences between MetALD and MASLD – Prof. Ajay Duseja, India View Bio |
|
Specific aetiology SLD in the Asian context – Dr. Daniel Huang Qingyao, Singapore View Bio |
|
Combined Q&A | |
Tea Break | |
Chairs: Dr. Daniel Huang & Prof. Ming-Hua Zheng | |
Interpreting NIT data: Lessons from NIMBLE and LITMUS – Prof. Arun Sanyal, USA View Bio |
|
Intelligent use of NIT’s in clinical practice – moving forward and back from primary care – Prof. Chan Wah Kheong, Malaysia View Bio |
|
A patient centric view of risk assessment: balancing competing risks – Dr. Mark Muthiah, Singapore View Bio |
|
Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics – Dr. Dean Tai, Singapore View Bio |
|
Combined Q&A | |
UITC & ECHOSENS Lunch Symposium | |
Asia Perspective on Fatty Liver Disease – Dr. George Goh, Singapore View Bio |
|
Optimizing VCTETM assessment of MASLD – Prof. Vincent Wong, Hong Kong View Bio |
|
Q&A Session | |
FibroScan® 630 Expert SSM Demo Session | |
Chairs: Dr. Edhel Tripon & Dr. Anand Kulkarni | |
Debate: Will incretin-based obesity treatment solve the MASLD epidemic? – Yes: Dr. Jiangao Fan, China View Bio – No: Prof. Vincent Wong, Hong Kong View Bio |
|
An oasis in the desert: Understanding the THRß _pathway and its agonism in MASLD – Prof. Paul M. Yen, Singapore View Bio |
|
Future of FGF21 in treatment of MASLD – Prof. Arun Sanyal, USA View Bio |
|
Future of PPAR in treatment of MASLD – Prof. Sven Francque, Belgium View Bio |
|
Can data for bariatric surgery be extrapolated to endobariatrics for MASLD? – Dr. George Goh, Singapore View Bio |
|
Combined Q&A | |
Tea Break | |
Chairs: Prof. Ajay Duseja & Prof. Phunchai Charatcharoenwitthaya | |
State of the art: Why are we not making progress with cirrhotic MASH patients? – Prof. Arun Sanyal, USA View Bio |
|
Special considerations in managing the decompensated MASH cirrhotic patient –Dr. Mark Muthiah, Singapore View Bio, |
|
Case based discussion
– Moderators:
– Panel Speakers: |
|
Combined Q&A | |
Closing: National health policy for MASLD Prof. Dan Yock Young,Singapore View Bio |